Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.

Marta López-FauquedMaribel Co-van der MeeAdriana BastidasPierre BeukelaersAlemnew F DagnewJuan Jose Fernandez GarciaAnne SchuindFernanda Tavares-da-Silva

Published in: Drug safety (2021)

Recombinant zoster vaccine has a clinically acceptable safety profile. With the previously published vaccine efficacy and immunogenicity results, these data support a favorable benefit-risk profile of RZV vaccination in immunocompromised populations who are at an increased risk of herpes zoster.

Keyphrases

respiratory failure
genetic diversity
big data
intensive care unit
machine learning
extracorporeal membrane oxygenation
artificial intelligence